USPTO serial 88769614
JEEVA
Reviewed by CopyMark Law Group
Reg. 6925350Status 790Registered
- Filing date
- Status date
- Registration date
- Dec 13, 2022
- Examiner
- SULLIVAN, JOHN C
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with JEEVA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Jeeva Informatics Solutions, Inc.
Herndon, VA, US
Jeeva Informatics Solutions, Inc.
Herndon, VA, US
Jeeva Informatics Solutions, Inc.
Herndon, VA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
CELESTE M. BUTERA
CELESTE M. BUTERA LIPPES MATHIAS, LLP445 BROADHOLLOW ROADSUITE 420MELVILLE, NY 11747Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Business consulting and management in the field of clinical trials, namely, providing information management services; business consulting and management in the field of clinical trials; business consulting and management in the field of regulatory submission management, namely, clinical trial data integrity and immutability; database management in the field of clinical trials; updating and maintenance of data in computer databases in the field of clinical trials | ACTIVE | Apr 14, 2022 |
| 042 | Software as a service (SAAS) services featuring software for the processing and analysis of data using artificial intelligence and natural language processing; Software as a service (SAAS) services featuring software for planning, management and operational management in the field of clinical trials and long-term health management; Software as a service (SAAS) services featuring software featuring machine learning technology for planning, management, operational management, and study design optimization in the field of clinical trials and long-term health management; Software as a service (SAAS) services featuring software for estimating the probability of clinical trial success; Software as a service (SAAS) services featuring software featuring machine learning technology for capturing, collecting, managing, analyzing, and reporting data from clinical trials and drug discovery for use in database management and processing data; scientific consulting services in the field of conducting clinical trials for others; information technology consulting services relating to the collection, review, analysis and reporting of clinical trial, drug development, drug discovery information; providing medical and scientific research information in the field of clinical trials; providing online searchable databases featuring medical and scientific research clinical trial information whereby users can input and collect data and information for research purposes; pharmaceutical research and development information services in the field of health care and clinical trials; Software as a service (SAAS) services featuring software for real-time and long-term patient monitoring and safety review in the field of clinical trials; Software as a service (SAAS) services featuring software for the processing and analysis of data for use in the discovery of disease biomarkers for diagnostic and therapeutic purposes; structural and functional analysis of genomes; database development services, namely, providing configuration and customization of computer databases in the field of medical information related to clinical trials and late phase research; database development services, namely, providing configuration and customization of computer databases in the field of medical information related healthcare and long-term health management; medical research, namely, compiling and analyzing genomics data for use in the discovery of disease biomarkers which are used for diagnostic and therapeutic purposes | ACTIVE | Apr 14, 2022 |
| 044 | Medical services, namely, medical advice relating to the design of clinical trials, late phase research, adverse event reporting and safety monitoring of clinical trials; medical services, namely, medical advice relating to long-term health management | ACTIVE | Apr 14, 2022 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Jeeva Informatics Solutions, Inc.
- Other trademarks owned by Jeeva Informatics Solutions, Inc.
- Other trademarks owned by Jeeva Informatics Solutions, Inc.
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named JEEVA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 29, 2026 | PETC | CANCELLATION INSTITUTED NO. 999999 | — |
| Dec 13, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 13, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 8, 2022 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Nov 5, 2022 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Nov 4, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 4, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 4, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 28, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 28, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 28, 2022 | CNRT | SU - NON-FINAL ACTION - WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 28, 2022 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Sep 27, 2022 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Sep 14, 2022 | IUAF | USE AMENDMENT FILED | — |
| Sep 14, 2022 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Jul 12, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 8, 2022 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Jul 8, 2022 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jul 8, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 11, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 7, 2022 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jan 7, 2022 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jan 7, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 5, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 3, 2021 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jun 3, 2021 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jun 3, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 8, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 6, 2021 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jan 6, 2021 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jan 6, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 21, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 26, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 26, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 6, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 20, 2020 | ALIE | ASSIGNED TO LIE | — |
| Apr 13, 2020 | LOPR | LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN | — |
| Apr 13, 2020 | LOPT | LETTER OF PROTEST EVIDENCE FORWARDED | — |
| Apr 9, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 9, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 9, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 9, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 9, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 9, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 27, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 25, 2020 | NWAP | NEW APPLICATION ENTERED | — |